AIM: To share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine
Established in 2003, the Global HIV Vaccine Enterprise became a programme of the IAS in 2018. It works to engage stakeholders and funders to accelerate HIV vaccine development and prepare the field for the future discovery of a safe, effective and globally accessible HIV vaccine.
It does so by:
Strengthening the HIV vaccine pipeline by encouraging diverse approaches in HIV vaccine research and advancing the HIV vaccine portfolio
Expandingand diversifying engagement and resources by fostering interest in HIV vaccine R&D and broadening research talent within the HIV vaccine field
Mobilizing knowledge to accelerate product development by driving opportunities to address unanswered scientific questions and leveraging synergies with other infectious disease research
This project was sponsored by the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Aids (DAIDS) and administered through a grant by CRDF Global.